News & Updates

The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.

Among systemic lupus erythematosus patients, SARS-CoV-2-specific immune responses after BNT162b2 vaccination seem to be impaired in the presence of poor baseline humoral immune status, low naïve B cell frequencies, and mycophenolate mofetil (MMF) and methotrexate (MTX) use, according to a study.

Angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) appear to be beneficial to chronic obstructive pulmonary disease (COPD) patients, with a recent study suggesting that the use of such drugs may slow down progression of emphysema and lung function decline.

Survival benefit in patients with de novo stage IV nonsmall-cell lung cancer (NSCLC) depends on the type of treatment received, with significantly better median overall survival (OS) seen with the use of small-molecule targeted therapy against epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements than with best supportive care, reports a study.

Ketone supplements containing β-hydroxybutyrate yield potential neurocognitive benefits in individuals with obesity, specifically bolstering cognitive function and increasing cerebral blood flow, as reported in a recent study.